JAMA neurology Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Association of Cardiovascular Events With Spouse's Subsequent Dementia..  81:1098-1099. 2024
• Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome..  81:1066-1072. 2024
• MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population..  81:1051-1059. 2024
• Perceived CTE and Suicidality-Is Perception Reality? 2024
• Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer Disease..  81:619-629. 2024
• Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders: A Review..  81:645-653. 2024
• Harnessing Brain Pathology for Dementia Prevention..  81:229-231. 2024
• A New Framework for Dementia Nomenclature..  80:1364-1370. 2023
• Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease..  80:1353-1363. 2023
• Declines in Wealth Among US Older Adults at Risk of Dementia..  80:1250-1252. 2023
• Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity..  80:1051-1061. 2023
• Associations of Sex, Race, and Apolipoprotein E Alleles With Multiple Domains of Cognition Among Older Adults..  80:929-939. 2023
• Characteristics of Emergency Department Visits Among Older Adults With Dementia..  80:1002-1004. 2023
• Dementia Risk and Disadvantaged Neighborhoods..  80:903-909. 2023
• Association Between Acute Myocardial Infarction and Cognition..  80:723-731. 2023
• Myocardial Infarction Bends the Curve of Age-Related Cognitive Decline, but How?.  80:665-667. 2023
• Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers..  80:82-90. 2023
• Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study..  79:1139-47. 2022
• Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment..  79:975-985. 2022
• Reproductive Rights in Neurology-The Supreme Court's Impact on All of Us..  79:961-962. 2022
• Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition..  79:1025-1035. 2022
• Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease..  79:835-836. 2022
• Addition of Vision Impairment to a Life-Course Model of Potentially Modifiable Dementia Risk Factors in the US..  79:623-626. 2022
• Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease..  79:592-603. 2022
• Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US..  79:584-591. 2022
• Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial..  79:380-389. 2022
• Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum..  79:228-243. 2022
• Modernizing Psychiatry Training for Neurologists-From Off-Service to In-Service..  79:113-114. 2022
• Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial..  78:1324-1332. 2021
• Plasma Biomarkers of Tau and Neurodegeneration During Major Cardiac and Noncardiac Surgery..  78:1407-1409. 2021
• Agent Orange Exposure and Dementia Diagnosis in US Veterans of the Vietnam Era-Reply..  78:1277-1278. 2021
• Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging..  78:1187-1196. 2021
• Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes..  78:1108-1117. 2021
• Pathological Computed Tomography Features Associated With Adverse Outcomes After Mild Traumatic Brain Injury: A TRACK-TBI Study With External Validation in CENTER-TBI..  78:1137-1148. 2021
• APOE ε4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for All..  78:913-915. 2021
• Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study..  78:982-992. 2021
• Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California..  78:657-665. 2021
• Sexual and Gender Minority Health in Neurology: A Scoping Review..  78:747-754. 2021
• Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial..  78:568-577. 2021
• Agent Orange Exposure and Dementia Diagnosis in US Veterans of the Vietnam Era..  78:473-477. 2021
• Perils of Race-Based Norms in Cognitive Testing: The Case of Former NFL Players..  78:377-378. 2021
• Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial..  78:293-301. 2021
• Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment..  78:229-235. 2021
• Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment..  78:217-228. 2021
• Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial..  78:312-320. 2021
• Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis..  78:102-113. 2021
• Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment..  77:1504-1513. 2020
• Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease..  77:1288-1298. 2020
• Association of Circadian Abnormalities in Older Adults With an Increased Risk of Developing Parkinson Disease..  77:1270-1278. 2020
• Association of Rapid Eye Movement Sleep With Mortality in Middle-aged and Older Adults..  77:1241-1251. 2020
• Association of Racial Residential Segregation Throughout Young Adulthood and Cognitive Performance in Middle-aged Participants in the CARDIA Study..  77:1000-1007. 2020
• Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza..  77:1-7. 2020
• Association Between Blood Pressure and Later-Life Cognition Among Black and White Individuals..  77:810-819. 2020
• Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes..  77:829-839. 2020
• Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals..  77:735-745. 2020
• Association of Late-Onset Unprovoked Seizures of Unknown Etiology With the Risk of Developing Dementia in Older Veterans..  77:710-715. 2020
• Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials..  77:755-763. 2020
• Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy..  77:517-521. 2020
• Epidemiology of Dementia and Alzheimer Disease in Individuals With Down Syndrome..  77:262-264. 2020
• Perception of Dementia Risk and Preventive Actions Among US Adults Aged 50 to 64 Years..  77:259-262. 2020
• Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease..  77:225-233. 2020
• Association of Neighborhood-Level Disadvantage With Cerebral and Hippocampal Volume..  77:451-460. 2020
• Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults..  76:1203-1210. 2019
• Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework..  76:1174-1183. 2019
• Recovery After Mild Traumatic Brain Injury in Patients Presenting to US Level I Trauma Centers: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Study..  76:1049-1059. 2019
• Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study..  76:915-924. 2019
• Apolipoprotein B as a New Link Between Cholesterol and Alzheimer Disease..  76:751-753. 2019
• Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults..  76:542-551. 2019
• Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration..  76:95-100. 2019
• Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome..  75:1399-1406. 2018
• Association of Mild Traumatic Brain Injury With and Without Loss of Consciousness With Dementia in US Military Veterans..  75:1055-1061. 2018
• Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study..  75:1124-1131. 2018
• Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting..  75:970-979. 2018
• Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau..  75:989-998. 2018
• Publication and Dissemination of Results in Clinical Trials of Neurology..  75:890-891. 2018
• Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia..  75:672-680. 2018
• Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease..  75:548-556. 2018
• Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease..  75:582-590. 2018
• Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis..  75:328-341. 2018
• Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia..  75:88-96. 2018
• Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden..  74:1455-1463. 2017
• Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis..  74:1178-1189. 2017
• Association of JNC-8 and SPRINT Systolic Blood Pressure Levels With Cognitive Function and Related Racial Disparity..  74:1199-1205. 2017
• Association of Sleep-Disordered Breathing With Cognitive Function and Risk of Cognitive Impairment: A Systematic Review and Meta-analysis..  74:1237-1245. 2017
• Reassuring News About Football and Cognitive Decline?: Not So Fast..  74:898-899. 2017
• Association of Dual-Task Gait With Incident Dementia in Mild Cognitive Impairment: Results From the Gait and Brain Study..  74:857-865. 2017
• Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex..  74:813-820. 2017
• Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals..  74:718-726. 2017
• Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design..  74:540-548. 2017
• Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System..  74:207-215. 2017
• Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E ε4 Genotype..  74:82-90. 2017
• Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases..  73:1334-1341. 2016
• Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease..  73:1217-1224. 2016
• Characteristic Neuroimaging Abnormalities of Korsakoff Syndrome..  73:1248-1249. 2016
• Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals..  73:1185-1191. 2016
• Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology..  73:1192-1200. 2016
• Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study..  73:1125-32. 2016
• Neuropathologic Associations of Learning and Memory in Primary Progressive Aphasia..  73:846-52. 2016
• Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults..  73:721-32. 2016
• Cerebrospinal Biomarkers in Alzheimer Disease-Potential Roles as Markers of Prognosis and Neuroplasticity..  73:508-10. 2016
• Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease..  73:447-55. 2016
• The Human Alzheimer Disease Project: Answering the Call..  73:373-4. 2016
• Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community..  73:85-92. 2016
• Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease..  73:561-71. 2016
• Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator..  73:50-9. 2016
• Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment..  72:1475-83. 2015
• Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study..  72:912-9. 2015
• Diabetes Mellitus and Cognitive Resilience--Reply..  72:949-50. 2015
• Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease..  72:699-706. 2015
• Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span..  72:511-9. 2015
• Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults..  72:546-53. 2015
• Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument..  72:446-54. 2015
• Cognitive resilience to apolipoprotein E ε4: contributing factors in black and white older adults..  72:340-8. 2015
• Rarity of the Alzheimer disease-protective APP A673T variant in the United States..  72:209-16. 2015
• Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease..  72:656-65. 2015
• Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age..  72:1029-42. 2015
• Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease..  72:1275-80. 2015
• Association between the prevalence of learning disabilities and primary progressive aphasia..  71:1576-7. 2014
• Congenital absence of apolipoprotein E and neurological function..  71:1578-9. 2014
• Dementia risk after traumatic brain injury vs nonbrain trauma: the role of age and severity..  71:1490-7. 2014
• White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration..  71:1547-54. 2014
• Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study..  71:1394-404. 2014
• Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals..  71:1379-85. 2014
• Translational research in acute central nervous system injury: lessons learned and the future..  71:1311-8. 2014
• Functional connectivity in autosomal dominant and late-onset Alzheimer disease..  71:1111-22. 2014
• The preclinical Alzheimer cognitive composite: measuring amyloid-related decline..  71:961-70. 2014
• Vitamin D and subclinical cerebrovascular disease: the Atherosclerosis Risk in Communities brain magnetic resonance imaging study..  71:863-71. 2014
• Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience..  71:710-6. 2014
• Human neurons derived from induced pluripotent stem cells as a new platform for preclinical drug screening and development..  71:1475-6. 2014
• Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial..  71:141-50. 2014
• Neuropathologic basis of age-associated brain atrophy..  70:616-22. 2013
• Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity..  70:1242-8. 2013
• SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy..  70:201-7. 2013
• Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis..  70:1030-8. 2013
• Sleep evaluation by actigraphy for patients with Alzheimer disease--reply..  70:1074-5. 2013
• Sleep quality and preclinical Alzheimer disease..  70:587-93. 2013

Identity

International Standard Serial Number (ISSN)

• 2168-6157